Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.10
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$4.10
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.79 - AU$6.39
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$1.02B
Enterprise ValueAU$488.88M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding162,963,610
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside48.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$13.77M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetA low and improving debt-to-equity ratio provides durable financial flexibility, reducing refinancing and interest-rate risk. This strengthens the company's ability to fund product development, pursue partnerships or pilot deployments and absorb near-term losses without urgent debt pressure.
AI-enabled Coronary Imaging FocusSpecialization in AI-driven coronary imaging targets a defined clinical niche with persistent demand from aging populations and rising cardiovascular diagnostics. A software-first clinical decision support model can scale, yield high incremental margins, and build defensible clinical adoption if validated by outcomes and workflow integration.
Initial Commercial Revenue And GrowthThe emergence of recorded revenue in FY2025 and a high percentage growth rate indicate early commercialization progress and product-market engagement. While base is small, establishing paid deployments creates a repeatable sales process and a pathway to scale revenue and demonstrate unit economics over the medium term.
Bears Say
Sustained Negative Operating Cash FlowPersistent operating and free cash outflows mean the business requires ongoing external funding to sustain operations and commercialization. Continued cash burn increases dilution risk or reliance on capital markets, constraining strategic options and potentially limiting investment in sales, validation studies and regulatory work.
Deep Operating Losses, No Demonstrated LeverageMaterial and persistent losses signal that the business model has not yet achieved scale or margin sustainability. Without clear operating leverage, incremental revenue may not translate into profit, delaying breakeven and weakening the firm's ability to self-fund growth or justify expansion investments over the medium term.
Declining Equity And Negative ROEShrinking equity and negative ROE reflect ongoing value erosion and demonstrate that capital invested to date has not delivered returns. This undermines investor confidence, can raise capital-raising costs, and signals structural challenges in converting R&D and early sales into profitable growth over the coming months.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.79 and its highest was AU$6.39 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$1.02B.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.06.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 162,963,610 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (48.78% Upside)
AU$6.10 (48.78% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$4.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(48.78% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
Options Prices
Currently, No data available
---







